Impact of regular enteral feeding via jejunostomy during neo-adjuvant chemotherapy on body composition in patients with oesophageal cancer

Table 1 Patient demographics

	No. of patients, n = 15
Age in yr, mean ± SD	61.3 ± 12.8
Sex
M	11 (73.3)
F	4 (26.7)
Tumour site
Mid oesophagus	1 (6.6)
Lower oesophagus	4 (26.7)
Oesophageal-gastric junction	10 (66.7)
Histology
Adenocarcinoma	11 (73.3)
Squamous cell cancer	3 (20.0)
Other	1 (6.7)
Stage
I	1 (6.6)
II	4 (26.7)
III	10 (66.7)
Neo-adjuvant chemotherapy protocol
ECX	7 (46.7)
ECF	3 (20)
EOX	1 (6.6)
CX	2 (13.3)
CF	2 (13.3)

Values are number of patients with percentages in parentheses unless indicated otherwise. SD: Standard deviation; M: Male; F: Female; ECX: Epirubicin/cisplatin/capecitabine; ECF: Epirubicin/cisplatin/5-fluorouracil; EOX: Epirubicin/oxaliplatin/capecitabine; CX: Cisplatin/capecitabine; CF: Cisplatin/5-fluorouracil.